820 related articles for article (PubMed ID: 16321428)
1. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
2. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
3. Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.
Fish JM; Di Diego JM; Nesterenko V; Antzelevitch C
Circulation; 2004 May; 109(17):2136-42. PubMed ID: 15078801
[TBL] [Abstract][Full Text] [Related]
4. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
5. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
6. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
7. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
8. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
10. Cellular mechanism of the QT prolongation induced by sulpiride.
Lee HA; Kim KS; Park SJ; Kim EJ
Int J Toxicol; 2009; 28(3):207-12. PubMed ID: 19546258
[TBL] [Abstract][Full Text] [Related]
11. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
13. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
14. The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.
Gao Z; Milnes JT; Choisy SC; Leach MJ; Hancox JC; James AF
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1088-96. PubMed ID: 16445575
[TBL] [Abstract][Full Text] [Related]
15. In silico risk assessment for drug-induction of cardiac arrhythmia.
Suzuki S; Murakami S; Tsujimae K; Findlay I; Kurachi Y
Prog Biophys Mol Biol; 2008 Sep; 98(1):52-60. PubMed ID: 18635251
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
17. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
Shantsila E; Watson T; Lip GY
Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
[TBL] [Abstract][Full Text] [Related]
19. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide.
Hanada E; Ohtani H; Hirota M; Uemura N; Nakaya H; Kotaki H; Sato H; Yamada Y; Iga T
J Pharm Pharmacol; 2003 Jul; 55(7):995-1002. PubMed ID: 12906757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
